ChromaDex Corp. announced that the European Food Safety Authority (EFSA) issued a positive opinion on nicotinamide riboside (NR) as a novel food ingredient for use in food supplements, at a serving of 300 mg daily, for the healthy adult population. Now NR will advance to the European Commission for review. Once the regulatory process for the European market is complete, ChromaDex plans to launch its flagship NR product Tru Niagen in the European Union (EU).
“Safety is paramount for ChromaDex and this positive opinion from EFSA underscores our depth of science, and is the latest in a consistently positive series of reviews of NR by authoritative bodies,” said ChromaDex CEO Rob Fried, in a press release. “We are diligently working to complete the regulatory process to bring NR to the health-conscious people of the EU.”